Navigation Links
New Arthritis Drug Linked to Increased Risk of Heart Attacks

The new arthritis drug Prexige is said to be linked to an increased risk of heart attacks and strokes and arthritis sufferers have been warned to exercise caution in its use.//

The federal government's Pharmaceutical Benefits Scheme (PBS) will make the drug Prexige (generic name, lumiracoxib) available from Tuesday. The drug is the first COX-2 inhibitor to be marketed in Australia since it was found in 2004 that these group of drugs increased risk of heart attacks and strokes.

Popular arthritis drug Vioxx was taken off shelves while the drug Celebrex was forced to carry warnings about heart disease ever since this revelation was made public in 2004. The National Prescribing Service has released an independent review warning that the evidence of long-term cardiovascular safety of the new drug is limited.

Dr Peter Roush from the National Prescribing Service says that the safer option for patients should be to first try to manage their condition with over-the-counter painkillers.

He said, "People with osteoarthritis should first consider an effective dose of paracetamol and speak with their doctor if they need a medicine to manage the pain. For some people, lumiracoxib may be an appropriate alternative to other medicines in the same class. This medicine has benefits for people at risk of a stomach ulcer, but we don't know everything about its risk to the heart and brain."

COX-2 inhibitors have been non-steroidal anti-inflammatory drugs (NSAIDs) which were developed as an alternative to older NSAIDs like ibuprofen, Voltaren, or naproxen. And studies showed that lumiracoxib caused fewer serious ulcer complications such as bleeding, than ibuprofen or naproxen. He said, "But people who are likely to have stomach trouble should use lumiracoxib with caution, as it does not eliminate the risk of getting an ulcer. There's limited evidence available about the long-term risk to your heart when using this medicine, but we do kn ow you should not use it if you have, or are likely to have, cardiovascular disease."

The medicine is recommended for use for the shortest possible time, ideally when symptoms flare up or before painful activities.


'"/>




Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
3. B Vitamin protects and lowers toxicity of Arthritis Drug
4. FDA Approves New Arthritis Drug, Bextra
5. Risk Of Developing Arthritis
6. Arthritis Drug May Cause Liver Damage
7. Arthritis drug can prolong life
8. New treatment for Rheumatoid Arthritis
9. Important cause of Arthritis
10. Personality Impacts Arthritis
11. New Rheumatoid Arthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management ... radiology marketing programs at the annual Building Better Radiology Marketing Programs conference, ... Hotel in Fort Worth, Texas. Nine awards are given out in five categories. They ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: